title: Bisphosphonate Withdrawal: Effects on Bone Formation and Bone Resorption in Maturing Male Mice.
abstract: Bisphosphonates are being increasingly used to treat pediatric patients with skeletal disorders. However, the effects of long-term bisphosphonate therapy and cessation of therapy during growth are unclear. Thus, studies were undertaken to determine the effects of alendronate discontinuation after treatment of C57Bl/6 mice during the period of rapid skeletal growth. Compared with vehicle-treated mice, 16 weeks of alendronate treatment starting at age 18 days resulted in a 3.7-fold increase in trabecular bone in the setting of suppressed bone formation. Alendronate therapy for 8 weeks followed by 8 weeks of vehicle treatment resulted in a more pronounced increase in trabecular bone compared with mice treated with alendronate for 16 weeks (1.7-fold) and to vehicle-treated controls (6.5-fold). Mice that received alendronate for 8 weeks followed by 8 weeks of vehicle exhibited increased osteoblast surface (2.5-fold), mineralizing surface (5.7-fold), and bone formation rate (5.1-fold) compared with mice treated continuously with alendronate. However, these parameters were not restored to the levels observed in the vehicle-treated mice. Thus, partial resumption of bone formation upon cessation of bisphosphonate therapy leads to a greater increase in trabecular bone than that found when bisphosphonates are administered continuously to growing mice. These data suggest that intermittent administration of bisphosphonates may optimize their beneficial effects on the growing skeleton. © 2017 American Society for Bone and Mineral Research.
authors.affiliation: Endocrine Unit, Massachusetts General Hospital, Boston, MA, USA.|Harvard Medical School, Boston, MA, USA.
authors.forename: Frank C
authors.initials: FC
authors.lastname: Ko
authors.affiliation: Harvard Medical School, Boston, MA, USA.|Department of Orthopedics, Beth Israel Deaconess Medical Center, Boston, MA, USA.
authors.forename: Lamya
authors.initials: L
authors.lastname: Karim
authors.affiliation: Endocrine Unit, Massachusetts General Hospital, Boston, MA, USA.|Department of Orthopedics, Beth Israel Deaconess Medical Center, Boston, MA, USA.
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Brooks
authors.affiliation: Endocrine Unit, Massachusetts General Hospital, Boston, MA, USA.|Harvard Medical School, Boston, MA, USA.|Department of Orthopedics, Beth Israel Deaconess Medical Center, Boston, MA, USA.
authors.forename: Mary L
authors.initials: ML
authors.lastname: Bouxsein
authors.affiliation: Endocrine Unit, Massachusetts General Hospital, Boston, MA, USA.|Harvard Medical School, Boston, MA, USA.
authors.forename: Marie B
authors.initials: MB
authors.lastname: Demay
mesh_terms: D000818:Animals; D001862:Bone Resorption / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D004164:Diphosphonates / Q000494:pharmacology*; D008297:Male; D051379:Mice; D010006:Osteoblasts / Q000378:metabolism / Q000473:pathology; D010012:Osteogenesis / Q000187:drug effects*
chemical_list: D004164:Diphosphonates
keywords: ANTIRESORPTIVES; BIOCHEMICAL MARKERS OF BONE TURNOVER; BONE HISTOMORPHOMETRY; BONE QCT/µCT; PRECLINICAL STUDIES